Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
01 août 2019 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports First Quarter 2019 Financial Results
14 mai 2019 07h00 HE
|
Iterum Therapeutics plc
On track to complete enrollment in all three Phase 3 clinical trials before year-end Filed patent application that may extend Iterum’s intellectual property rights into the 2040s DUBLIN,...
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
11 avr. 2019 07h30 HE
|
Iterum Therapeutics plc
The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen. Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to...
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
19 mars 2019 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
05 oct. 2018 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
25 sept. 2018 16h05 HE
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
18 sept. 2018 08h00 HE
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...